NEW YORK - The nitty-gritty of strategy, partnering and navigating the FDA were among topics covered during the fourth annual BIO CEO & Investor Conference last week, where about 1,500 registrants crowded the meeting rooms of the Waldorf-Astoria Hotel to hear some of the industry's leaders talk about what worked for them, and what didn't. (BioWorld Financial Watch)
NEW YORK - Partners matter. But products matter more, and the one can be used to reach the other, said Donald Drakeman, president and CEO of Medarex Inc., the transgenic mouse company with “about four dozen” collaborators. (BioWorld Today)
"Logjam" and "bottleneck" became popular words as the industry entered what became called the "post-genomic era" (and grew into yet another oft-used phrase). But everybody was talking about data, not drugs and that, of course, became the problem. While there was plenty of information, not much in the way of new treatments was coming out of it quickly. (BioWorld Financial Watch)
The high-stakes game continues. Like the smaller player in a lively pre-Valentine’s Day tennis match, ImClone Systems Inc. lobbed the ball back into Bristol-Myers Squibb Co.’s court early Tuesday, responding with a polite “no, thanks” to the pharmaceutical giant’s demand to change the terms of their deal regarding FDA-stalled Erbitux (cetuximab) for colorectal cancer. (BioWorld Today)
